Mizuho analyst Ann Hynes raised the firm’s price target on Charles River (CRL) to $174 from $155 and keeps a Neutral rating on the shares as part of a Q3 earnings preview for the healthcare facilities and managed care group. Healthcare utilization growth trends decelerated sequentially in Q3 despite easier year-over-year compares, which could indicate stabilizing cost trends, a positive for managed care companies, the analyst tells investors in a research note. The firm expects solid results from hospitals despite admissions trends falling sequentially. It is also “cautiously optimistic” that contract research organization trends have bottomed.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Strategic Divestiture and Value Unlocking: Charles River Labs’ Path to Growth
- Charles River, Toxys announce ReproTracker collaboration
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls